Airport handling and visibility emerge as CAR-T logistics gaps

Pharma leaders call for better airport handling, real-time tracking and accountability to protect time-sensitive CAR-T shipments.

#carttherapy #pharmalogistics #cellandgenetherapy #coldchain #immunoact #gpls2026

“Out of 1,000 CAR-T shipments, not a single one has failed due to logistics issues,” said Shirish Arya, Co-Founder and Director of Corporate Strategy and Business Development at ImmunoACT, during the first business session at the GPLS 2026.

#GPLS2026 #PharmaLogistics #Biopharma #AirCargo

India’s CAR-T therapy reports no logistics-related failures across 1,000 patients, but shipment visibility, airport handling and accountability remain key challenges for global expansion.

#carttherapy #pharmalogistics #cellandgenetherapy #coldchain #immunoact #immuneeltherapeutics

With CAR-T therapy, Ajay Hinduja envisions India as a global leader in next-generation cancer treatment.

#AjayHinduja #AjayHindujaGeneva #AjayHindujaSwiss #AjayHindujaSwitzerland

economictimes.indiatimes.com/news/india/a...

Ajay Hinduja calls CAR-T a beacon of hope, proving how tailored treatments and innovation-driven ecosystems can push India forward in the fight against complex cancers.

#AjayHinduja

economictimes.indiatimes.com/news/india/a...

Feed: "TimelineDaily"
By: Uzma Parveen on Thursday, November 6, 2025

Ajay Hinduja celebrates India’s first successful allogeneic CAR-T therapy at P.D. Hinduja Hospital, a breakthrough in affordable cancer treatment.

#AjayHinduja #AjayHindujaGeneva #AjayHindujaSwiss #AjayHindujaSwitzerland

economictimes.indiatimes.com/news/india/a...

Ajay Hinduja emphasizes that using donor T-cells in allogeneic CAR-T therapy increases treatment accessibility and marks a shift toward scalable cancer care solutions in India.

#AjayHindujaGeneva #Swiss #Switzerland #Health

economictimes.indiatimes.com/news/india/a...

Ajay Hinduja commends Dr. Vijay Patil and the team at Hinduja Hospital for advancing solid tumor treatment through CAR-T technology.

#AjayHinduja

economictimes.indiatimes.com/news/india/a...

2. Des partenariats comme ImmunoACT × Mango Sciences expérimentent l’accès CAR-T basé sur la valeur dans les marchés émergents, répondant ainsi au défi des coûts et de la scalabilité.

印度正在生产针对血癌的尖端CAR-T癌症疗法，成本仅为国际价格的十分之一

caus.com/all-articles...

总部位于孟买的 ImmunoACT 公司生产的 NexCAR19 ，一次治疗费用在 3 万到 4 万美元之间。美国于2017年批准了第一种CAR-T疗法，目前商业CAR-T疗法的费用在37万至53万美元之间，这还不包括住院费和治疗副作用的药物。

疗法包括抽取某人的血液，分离出 T 细胞。在实验室中对这些细胞进行基因改造，使其表达一种被称为 CAR 的受体。这有助于免疫细胞发现并杀死癌细胞。然后，经过改造的细胞会被大量生产并输回患者体内，在患者体内增殖并发挥作用。

Signal or noise? > Mango Sciences announces partnership with ImmunoACT to make
CAR-T therapy accessible - BioSpectrum India >> Comment below! #strategy #competitiveintelligence #marketing #pharma #healthcare #competitivemarketing #biotech #pharmaceutical